Influence of route of 17β-oestradiol and type of gestagen used on plasma glucose and insulin concentration in postmenopausal women
Journal Title: Przegląd Menopauzalny - Year 2006, Vol 26, Issue 4
Abstract
Aim: Comparison of the influence of transdermal and oral route of 17β-oestradiol administration and type of gestagen on plasma glucose and insulin concentration in postmenopausal women. Materials and methods: 62 women were enrolled in the study. Group A – 25 women received transdermal 17β-oestradiol (Oesclim 50 – Fournier-Solvay) combined with 5 mg oral dydrogesterone daily (Duphaston – Solvay). Group B – 10 women received oral 17β-oestradiol combined with 10 mg of dydrogesterone daily administration (Femoston-Solvay). Group C – 17 women received transdermal 17β-oestradiol (Oesclim 50 – Fournier-Solvay) combined with 5 mg daily oral medroxyprogesterone (Gestomikron – Adamed). Group D – 10 women without treatment. Basic plasma FSH, oestradiol, glucose and insulin as well as glucose and insulin at the 60th minute of OGTT were measured initially and at the 6th and 12th month of the study. Results: The mean plasma glucose level during OGTT was reduced after 12 months of replacement therapy in group A. Mean plasma fasting glucose was reduced also after 12 months of oral replacement therapy in group B. The mean plasma fasting and glucose stimulated insulin concentrations were higher after 12 months of replacement therapy in group C. No changes in plasma glucose and insulin concentrations were observed in control group D. Conclusion: Administration of hormone replacement therapy may influence the metabolism of glucose and insulin in postmenopausal women according to the type of gestagen applied.
Authors and Affiliations
Tomasz Milewicz, Iwona Rogatko, Dorota Skucińska, Józef Krzysiek, Krystyna Sztefko, Ewa Kwiatkowska-Panek, Stanisław Radowicki
Keywords
Related Articles
- EP ID EP139128
- DOI -
- Views 67
- Downloads 0
Influence of IGF-I and IGFBP-3 on bone mineral density in postmenopausal women
Aim of study: Serum concentration of insulin-like growth factor-I (IGF-I) decreases with age but the link between IGF-I and postmenopausal osteoporosis remains controversial. IGFBP-3 is IGF-I binding protein, which pro...
Niskodawkowa, dwuskładnikowa doustna antykoncepcja u kobiet w okresie pre- i okołomenopauzalnym
Niskodawkowa, dwuskładnikowa tabletka antykoncepcyjna jest atrakcyjną formą antykoncepcji dla kobiet menopauzalnych. Będąc metodą o wysokiej skuteczności zapobiegania ciąży, wywiera jednocześnie wiele korzystnych efektów...
Low-dose combined oral contraception in women in pre- and perimenopausal period
Low-dose combined contraceptive tablet is an attractive form of contraception for menopausal women. A method of high contraceptive efficacy, it produces some extra-contraceptive effects, alleviating vasomotor symptoms, p...
Korzyści wcześnie wdrożonej estrogenowej terapii zastępczej u pacjentek po menopauzie chirurgicznej
Menopauza chirurgiczna w następstwie salpingooforektomii u pacjentek premenopauzalnych prowadzi do nagłego spadku stężenia estradiolu w surowicy krwi i w efekcie do wielokierunkowych niekorzystnych następstw hipoestrog...
Niskie dawki w terapii hormonalnej okresu menopauzy
Niskie dawki estrogenów i progestagenów są coraz popularniejszymi formami w terapii hormonalnej kobiet w okresie menopauzy. Niskodawkowa terapia hormonalna (HT), przy porównywalnej skuteczności terapeutycznej, daje mni...